113 results
Page 3 of 6
8-K
EX-99.1
7exxm30cue5nc
25 Apr 23
Results of Operations and Financial Condition
4:31pm
PRE 14A
enw02f2
7 Apr 23
Preliminary proxy
4:02pm
8-K
EX-99.2
v3u3139sk7hyu
3 Nov 22
Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates
7:02am
8-K
EX-99.1
s3krtzg5gwb
6 Sep 22
Regulation FD Disclosure
5:01pm
8-K
EX-99.2
rlu7sh477b46dryaces
4 Aug 22
Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates
6:01am
424B5
n9c8sgj
20 May 22
Prospectus supplement for primary offering
4:02pm
424B5
crf mybbciq
6 May 22
Prospectus supplement for primary offering
7:15am
8-K
EX-99.2
e781881c
5 May 22
Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates
6:34am
8-K
EX-99.1
q07r0ty1p3e2jioz552
5 May 22
Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates
6:34am
8-K
dlye8 9ba3h
12 Apr 22
Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD
6:02am
8-K
EX-99.3
dyddji1
12 Apr 22
Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD
6:02am
8-K
EX-99.1
nyx rjquflc0bk
12 Apr 22
Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD
6:02am
8-K
EX-99.1
61ii 2aq9u9g16adi0
8 Mar 22
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Program Updates
7:04am